Screener
Ultragenyx Pharmaceutical RARE Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $214M+28.1% | $136M-2.2% | $207.28M+25.9% | $159.93M+14.7% | $167M+13.6% | ||
| $167M+1.2% | $187M+12.7% | $203.28M+8.2% | $216.21M+27.1% | $165M+2.2% | ||
| $88M+1.1% | $88M+1.1% | $87.94M+7.4% | $86.62M+7.8% | $87M+7.9% | ||
| -$75M+30.6% | -$169M-18.2% | -$113.28M+7.4% | -$170.89M-29.5% | -$108M+7.2% | ||
| -35%+29.6pp | -124.3%-21.4pp | -54.7%+19.6pp | -106.9%-12.2pp | -64.7%+14.5pp | ||
| $1M-50.0% | —— | —— | -$1.04M-134% | $2M+209% | ||
| -$91M+20.2% | -$184M-22.7% | -$127.69M+3.9% | -$179.54M-34.8% | -$114M+12.8% | ||
| $1M0.0% | $1M0.0% | $870K+127% | $873K+188% | $1M+16.6% | ||
| -$92M+20.0% | -$185M-22.5% | -$128.56M+3.5% | -$180.41M-35.1% | -$115M+12.6% | ||
| -43%+25.9pp | -136%-27.4pp | -62%+18.9pp | -112.8%-17.1pp | -68.9%+20.6pp | ||
| -$0.90+23.1% | -$1.84-17.2% | -$1.28+7.2% | -$1.81-29.3% | -$1.17+23.0% | ||
| -$67M+32.3% | -$161M-20.1% | -$104.5M+7.3% | -$162.68M-32.0% | -$99M+7.9% | ||
| -31.3%+28.0pp | -118.4%-22.0pp | -50.4%+18.1pp | -101.7%-13.4pp | -59.3%+13.8pp | ||
| -$75M+30.6% | -$169M-18.2% | -$113.28M+7.4% | -$170.89M-29.5% | -$108M+7.2% |
FAQ
- What is Ultragenyx Pharmaceutical's revenue?
- Ultragenyx Pharmaceutical (RARE) generated $717.2M in revenue over the trailing twelve months, up 17.5% year over year.
- Is Ultragenyx Pharmaceutical profitable?
- Ultragenyx Pharmaceutical is not currently profitable: it reported a net loss of $586.0M over the trailing twelve months, a -81.7% net margin.
- What are Ultragenyx Pharmaceutical's profit margins?
- Gross margin is 97.2% and operating margin is -73.6%, with a -81.7% net margin.
- What is Ultragenyx Pharmaceutical's earnings per share?
- Ultragenyx Pharmaceutical's diluted EPS over the trailing twelve months is $-5.83.
- Where does Ultragenyx Pharmaceutical's income statement data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
